Avacta Group (AVCT.L) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

AVCT.L · Stock Price

GBP 0.81+0.48 (+147.33%)

Market Cap: $498.5M

Historical price data

Market Cap: $498.5MPipeline: 2 drugsFounded: 2004HQ: Wetherby, United Kingdom

Sector Ranking#70 in Drug Delivery & Formulation #84 in Oncology (General)

Overview

Avacta Group is an AIM-listed biotech focused on developing targeted oncology therapies that improve the therapeutic index of potent cancer drugs. Its core achievement is the pre|CISION® platform, which has demonstrated a 100:1 tumor-to-plasma drug concentration ratio in clinical trials with its lead asset, AVA6000 (FAP-doxorubicin). The strategy involves evolving the platform through three generations—from rapid-release first-gen conjugates to sustained-release and dual-payload systems—to address a broad range of solid tumors (over 90% of which express FAP) and overcome resistance mechanisms. With two clinical-stage programs and a clear pipeline, Avacta aims to redefine cancer drug delivery.

OncologySolid Tumors

Technology Platform

The pre|CISION® platform is a tumor-activated peptide-drug conjugate (PDC) system that uses the protease Fibroblast Activation Protein (FAP) as a biological trigger to release potent cytotoxic payloads exclusively within the tumor microenvironment.

Pipeline

2

2 drugs in pipeline

Drug	Indication	Stage	Watch
AVA6000	Salivary Gland Tumor	Phase 1
AVA6103	Vulvar Adenocarcinoma	Phase 1

Funding History

3

Total raised:$78M

Placement$40MUndisclosedFeb 15, 2021

Placement$30MUndisclosedJul 15, 2020

IPO$8MUndisclosedJun 29, 2006

Opportunities

The pre|CISION® platform addresses over 90% of solid tumors via ubiquitous FAP expression, offering a pipeline-in-a-product opportunity to rejuvenate potent chemotherapies with improved safety.

Successful clinical validation could lead to high-value partnerships or acquisition by larger oncology-focused pharmaceutical companies seeking novel delivery technologies.

Risk Factors

The investment is highly binary on clinical data; failure of lead assets AVA6000 or AVA6103 to show compelling efficacy would severely impact valuation.

As a pre-revenue company, Avacta faces significant dilution risk from future capital raises needed to fund trials, and it operates in an intensely competitive landscape dominated by large pharma and other targeted therapy platforms.

Competitive Landscape

Avacta competes with antibody-drug conjugate (ADC) leaders like AstraZeneca and Gilead, as well as other tumor-activated prodrug platforms. Its key differentiation is the specificity of its FAP-triggered release mechanism and its sustained-release chemistry, which aims to concentrate drug exposure in the tumor more precisely than broader protease-cleavable ADC linkers.